Trial reportOpen forum infectious diseases2025
Linezolid-related Optic Nerve Disorders: Insight From a Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System.
Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Linezolid is a crucial oxazolidinone used to treat multidrug-resistant gram-positive infections; however, it is associated with optic neuropathy and other adverse events. Data regarding the usage and toxicity features of linezolid and those of tedizolid, a related agent with a potentially improved safety profile, are limited. Therefore, this study aimed to investigate the signals and characterize the clinical features of optic nerve disorders related to oxazolidinones using the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: This retrospective pharmacovigilance study examined FAERS data from July 2014 to April 2024. Disproportionality analyses (reporting odds ratio [ROR] and information component [IC]) were conducted to detect signals of oxazolidinone-related optic nerve disorders. Firth-type penalized logistic regression was used to further characterize the features of optic nerve disorders by comparing them with other adverse events (AEs). Results: In total, 15 350 730 reports were retrieved from the FAERS database, from which signals (defined as ROR > 1 and IC > 0) were detected only for linezolid, consistent with sensitivity analyses. Compared with other linezolid-related AEs, linezolid-related optic nerve disorders were characterized by younger age (<60 years; adjusted odds ratio [OR]: 6.86, 95% confidence interval [CI]: 2.36-26.51, Conclusions: Among oxazolidinones, a signal for optic nerve disorders was detected exclusively for linezolid. Clinicians should ensure regular ophthalmologic monitoring during linezolid treatment, particularly in younger patients and those receiving high cumulative doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.